Mayo Clinic researchers have validated a blood test's high precision for diagnosing patients with cognitive impairment.This non-invasive, cost-effective breakthrough, detailed in Alzheimer's & Dementia, offers much-needed hope for earlier intervention and better management.
Alzheimer's disease, a devastating neurological condition characterised by progressive memory loss and cognitive decline, affects millions worldwide. The profound impact extends beyond patients to their families and caregivers. While new treatments are emerging for individuals in the early stages of the disease, a critical challenge remains: the need for accessible, cost-effective, and accurate diagnostic tools to identify Alzheimer's sooner.
In a significant stride forward, Mayo Clinic researchers have validated the accuracy of an FDA-approved blood test that promises to revolutionise Alzheimer's diagnosis. This accessible test, suitable for use in outpatient memory clinics, demonstrated high accuracy in diagnosing the disease across a spectrum of cognitive impairments. The groundbreaking findings are published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Traditionally, diagnosing Alzheimer's disease has relied on methods such as positron emission tomography (PET) scans and spinal taps, which measure the buildup of toxic proteins in the brain. However, these procedures are often expensive and invasive, limiting their widespread applicability. The urgent need for more accessible, non-invasive, and cost-effective biomarkers – measurable indicators of a disease – has been a driving force in Alzheimer's research. This new blood test addresses that critical need, paving the way for improved diagnoses in diverse clinical settings.
The research team highlights the immense potential of their findings, stating that this blood test can significantly contribute to better identifying research participants with Alzheimer's disease brain changes, efficiently screening and selecting patients with Alzheimer's disease for clinical trials, and more effectively assessing patient response to therapy in clinical trials.
The study involved over 500 patients receiving treatment for various memory issues at the outpatient Memory Disorder Clinic at the Mayo Clinic in Florida. The diverse patient cohort included individuals with early- and late-onset cognitive impairment, typical and atypical Alzheimer's disease, Lewy body dementia, and vascular cognitive impairment. Patients ranged in age from 32 to 89, with the average age of symptom onset at 66. Alzheimer's disease was determined to be the underlying cause of symptoms in 56% of the participants. The research team also conducted serum tests to measure kidney disease, a factor that can influence plasma biomarker concentrations.
Mayo Clinic Laboratories conducted tests for two key proteins in blood plasma associated with amyloid plaque buildup, the hallmark of Alzheimer's disease: Aβ42/40 and p-tau217. The results revealed significantly higher levels of p-tau217 in patients diagnosed with Alzheimer's disease compared to those without the condition. Importantly, the researchers also observed that higher plasma p-tau217 concentrations were associated with impaired kidney function, underscoring the importance of considering this factor when interpreting blood test results.
Out of 509 patients, plasma p-tau217 concentrations were positive in 267 individuals. Notably, this included 233 out of 246 patients (95%) whose cognitive impairment was attributed to Alzheimer's disease, demonstrating the test's remarkable accuracy.
The study's compelling findings were prominently featured at the American Academy of Neurology Annual Meeting in April, generating significant interest within the medical community. This research builds upon a previous study by the Mayo Clinic Laboratories team, which demonstrated the utility of these blood tests in comparison to amyloid PET scans in research participants.
Looking ahead, Dr. Day, a lead researcher on the study, emphasised the next crucial steps. The team plans to evaluate blood-based testing in more diverse patient populations and in individuals with early Alzheimer's disease who may not yet exhibit cognitive symptoms. Furthermore, they aim to investigate disease-specific factors that could potentially alter biomarker accuracy in clinical trials.
This breakthrough in blood testing offers a promising future for Alzheimer's diagnosis, enabling earlier intervention, facilitating more effective clinical trials, and ultimately providing new hope for patients and their families.
Delegates from foreign ministries of Iran, China, and Russia met in Tehran on Tuesday to discuss the latest developments in Iran’s nuclear program p...
Two people have died and two others are being treated in hospital for serious injuries following a shooting incident in the Northern Ireland county of...
Kazakhstan and China have launched a pilot project using autonomous freight trucks at the Bakhty-Pokitu crossing, aiming to speed up customs procedure...
Sanctions are one of the most powerful foreign policy tools that countries use to influence international behaviour, short of going to war. But how do...
Türkiye and Britain have signed a memorandum of understanding on Wednesday to allow Ankara to become a user of Eurofighter Typhoon fighter jets, mark...
Every Sunday evening at Chicago’s North Avenue Beach, the sound of collective shouting echoes across Lake Michigan – not from protestors, but from Scream Club Chicago, a group gathering to relieve stress by screaming into the open air.
British researchers have announced a major scientific milestone: eight babies have been born healthy through a revolutionary technique that combines DNA from three individuals to eliminate the risk of passing on severe mitochondrial diseases.
Mozambique has reported a surge of monkey pox cases, with Niassa province the hardest hit. The northern province of Niassa in Mozambique is facing the most severe impact from the virus outbreak.
In 2024, one million more children completed the full three-dose vaccination series for diphtheria, tetanus, and whooping cough (DTP) than in the previous year, according to a new report from the World Health Organization (W.H.O.) and United Nations Children's Fund (UNICEF).
The world’s biggest dance music festival faces an unexpected setback as a fire destroys its main stage, prompting a last-minute response from organisers determined to keep the party alive in Boom, Belgium.
Iran launched 18 ballistic missiles late Sunday targeting the U.S. military’s Al-Udeid Air Base in Qatar, the largest American installation in the Middle East.
Australian researchers have created a groundbreaking “biological AI” platform that could revolutionise drug discovery by rapidly evolving molecules within mammalian cells.
Australian researchers have pioneered a low-cost and scalable plasma-based method to produce ammonia gas directly from air, offering a green alternative to the traditional fossil fuel-dependent Haber-Bosch process.
A series of earthquakes have struck Guatemala on Tuesday afternoon, leading authorities to advise residents to evacuate from buildings as a precaution against possible aftershocks.
Every Sunday evening at Chicago’s North Avenue Beach, the sound of collective shouting echoes across Lake Michigan – not from protestors, but from Scream Club Chicago, a group gathering to relieve stress by screaming into the open air.
A major study warns that antibiotic-resistant superbugs could kill millions each year while shrinking the global economy by almost $2 trillion annually by 2050, a crisis driven in part by international aid cuts that undermine resistance efforts.
The United States has rejected a global pandemic treaty adopted by the World Health Organization (WHO), saying it threatens national sovereignty and lacks clear language.
Ukrainian President Volodymyr Zelenskyy announced on Thursday that Deputy Prime Minister Olha Stefanishyna, who currently oversees European and Euro-Atlantic integration, has been appointed as Ukraine’s next ambassador to the United States.
British researchers have announced a major scientific milestone: eight babies have been born healthy through a revolutionary technique that combines DNA from three individuals to eliminate the risk of passing on severe mitochondrial diseases.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment